Trial Profile
Effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 12 Dec 2015 New trial record